Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's

Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's
Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's
Alex Carchidi, The Motley Fool

If you could get a coronavirus inoculation this afternoon, you probably wouldn't care if the clinician told you that the shot might feel a bit chilly. Will Moderna's (NASDAQ: MRNA) newly proven vaccine outperform its competitor made by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), which is likely to obtain regulatory approval and subsequently hit the market at roughly the same time? Moderna's mRNA-1273 isn't any more effective than Pfizer's candidate when it comes to preventing infection.